Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/163953
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa

AutorSánchez-Cruz, Alonso CSIC; Villarejo-Zori, Beatriz CSIC ORCID ; Marchena, Miguel CSIC; Zaldívar-Díez, Josefa CSIC ORCID; Palomo, Valle CSIC ORCID ; Gil, Carmen CSIC ORCID ; Lizasoain, Ignacio; de la Villa, P.; Martínez Gil, Ana CSIC ORCID ; De la Rosa, Enrique J. CSIC ORCID ; Hernández-Sánchez, Catalina
Fecha de publicación16-abr-2018
EditorBioMed Central
CitaciónMolecular Neurodegeneration 13(1): 19 (2018)
ResumenAbstract Background Retinitis pigmentosa (RP) is a group of hereditary retinal neurodegenerative conditions characterized by primary dysfunction and death of photoreceptor cells, resulting in visual loss and, eventually, blindness. To date, no effective therapies have been transferred to clinic. Given the diverse genetic etiology of RP, targeting common cellular and molecular retinal alterations has emerged as a potential therapeutic strategy. Methods Using the Pde6b rd10/rd10 mouse model of RP, we investigated the effects of daily intraperitoneal administration of VP3.15, a small-molecule heterocyclic GSK-3 inhibitor. Gene expression was analyzed by quantitative PCR and protein expression and phosphorylation by Western blot. Photoreceptor preservation was evaluated by histological analysis and visual function was assessed by electroretinography. Results In rd10 retinas, increased expression of pro-inflammatory markers and reactive gliosis coincided with the early stages of retinal degeneration. Compared with wild-type controls, GSK-3β expression (mRNA and protein) remained unchanged during the retinal degeneration period. However, levels of GSK-3βSer9 and its regulator AktSer473 were increased in rd10 versus wild-type retinas. In vivo administration of VP3.15 reduced photoreceptor cell loss and preserved visual function. This neuroprotective effect was accompanied by a decrease in the expression of neuroinflammatory markers. Conclusions These results provide proof of concept of the therapeutic potential of VP3.15 for the treatment of retinal neurodegenerative conditions in general, and RP in particular.
Versión del editorhttps://doi.org/10.1186/s13024-018-0251-y
URIhttp://hdl.handle.net/10261/163953
DOI10.1186/s13024-018-0251-y
E-ISSN1750-1326
Aparece en las colecciones: (CIB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
13024_2018_Article_251.pdf3,6 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

19
checked on 04-mar-2024

SCOPUSTM   
Citations

25
checked on 14-mar-2024

WEB OF SCIENCETM
Citations

23
checked on 29-feb-2024

Page view(s)

338
checked on 18-mar-2024

Download(s)

211
checked on 18-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.